Indian Court Restrains Cipla From Exporting Generic Tarceva
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - The Delhi High Court ordered Indian drugmaker Cipla to refrain from exporting a generic version of Roche's locally patented lung cancer drug Tarceva (erlontinib) to nations where the Swiss company has patent registration for the product, a court official said